Consolidated Planning Corp Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Consolidated Planning Corp grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 2,059.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,188 shares of the company’s stock after acquiring an additional 57,401 shares during the quarter. Consolidated Planning Corp’s holdings in AstraZeneca were worth $4,689,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Stratos Wealth Advisors LLC lifted its position in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after buying an additional 133 shares in the last quarter. Bruce G. Allen Investments LLC boosted its holdings in AstraZeneca by 19.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after buying an additional 138 shares during the period. Carnegie Investment Counsel lifted its position in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after acquiring an additional 138 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its stake in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the period. Finally, Sunpointe LLC lifted its holdings in AstraZeneca by 4.5% in the 2nd quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock worth $267,000 after purchasing an additional 147 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Trading Up 1.3 %

Shares of NASDAQ AZN opened at $64.69 on Friday. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $77.98 and a two-hundred day simple moving average of $78.65. The firm has a market cap of $200.58 billion, a PE ratio of 31.25, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Analyst Upgrades and Downgrades

AZN has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.